• Explore /
  • Poster
  • / A phase 2/3 study of fianlimab, cemiplimab, plus chemotherapy versus cemiplimab plus chemotherapy in first-line treatment of advanced non-small cell lung cancer.

A phase 2/3 study of fianlimab, cemiplimab, plus chemotherapy versus cemiplimab plus chemotherapy in first-line treatment of advanced non-small cell lung cancer.

Abstract Video & Slides Poster

Authors

null

Nashat Gabrail

Gabrail Cancer and Research Center, Canton, OH

Nashat Gabrail , Miranda Gogishvili , Tamta Makharadze , Nana Chikhladze , Neil E. Faulkner , Santosh Nair , Emad Ibrahim , Daniel Brungs , Luke Dreisbach , Gopal Kunta , Solange Peters , Christopher Nguyen , Maria Ghattas , Siyu Li , Mark Salvati , Israel Lowy , Matthew G. Fury , Luca Paoluzzi , Tamar Melkadze

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT05800015

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr TPS8660)

DOI

10.1200/JCO.2024.42.16_suppl.TPS8660

Abstract #

TPS8660

Poster Bd #

518a

Abstract Disclosures

Similar Posters

First Author: Michael Leapman

First Author: Neil E. Faulkner

First Author: Kohei Shitara

First Author: Natalie I Vokes